Bris­tol My­er­s' next-gen im­munol­o­gy med busts Am­gen's Ote­zla in head-to-head study. Is a show­down com­ing?

In an im­munol­o­gy mar­ket packed with block­buster bi­o­log­ics, Bris­tol My­ers Squibb hopes that its oral drug for milder cas­es could carve out a lu­cra­tive foothold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER